{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:45:39Z","timestamp":1762004739225},"reference-count":22,"publisher":"Jaypee Brothers Medical Publishing","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.4103\/0972-5229.167036","type":"journal-article","created":{"date-parts":[[2015,10,9]],"date-time":"2015-10-09T07:06:01Z","timestamp":1444374361000},"page":"587-592","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetic\/pharmacodynamic profiling of imipenem in patients admitted to an intensive care unit in India: A nonrandomized, cross-sectional, analytical, open-labeled study"],"prefix":"10.5005","volume":"19","author":[{"given":"B.","family":"Abhilash","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chakra","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anoop","family":"Gogia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish","family":"Meshram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manu","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Suraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2914","published-online":{"date-parts":[[2015]]},"reference":[{"key":"ref=1","unstructured":"1. Gupta E, Mohanty S, Sood S, Dhawan B, Das BK, Kapil A. Emerging resistance to carbapenems in a tertiary care hospital in North India. Indian J Med Res 2006;124:95-8."},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"2. Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong EL, Gin T. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001;47:421-9.","DOI":"10.1093\/jac\/47.4.421"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"3. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: An environmental point prevalence study. Lancet Infect Dis 2011;11:355-62.","DOI":"10.1016\/S1473-3099(11)70059-7"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"4. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: Epidemiology and prevention. Clin Infect Dis 2011;53:60-7.","DOI":"10.1093\/cid\/cir202"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"5. Belzberg H, Zhu J, Cornwell EE 3 rd, Murray JA, Sava J, Salim A, et al. Imipenem levels are not predictable in the critically ill patient. J Trauma 2004;56:111-7.","DOI":"10.1097\/01.TA.0000056164.26493.28"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"6. Giannoni E, Moreillon P, Cotting J, Moessinger A, Bille J, D\u00e9costerd L, et al. Prospective determination of plasma imipenem concentrations in critically ill children. Antimicrob Agents Chemother 2006;50:2563-8.","DOI":"10.1128\/AAC.01149-05"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"7. Lee LS, Kinzig-Schippers M, Nafziger AN, Ma L, S\u00f6rgel F, Jones RN, et al. Comparison of 30-min and 3-h infusion regimens for imipenem\/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis 2010;68:251-8.","DOI":"10.1016\/j.diagmicrobio.2010.06.012"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"8. Carlucci G, Biordi L, Bologna M. Human plasma and aqueous humor determination of imipenem by liquid chromatography with ultraviolet detection. J Liq Chromatogr 1993;16:2347-58.","DOI":"10.1080\/10826079308020991"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"9. Biswal S, Mishra P, Malhotra S, Puri GD, Pandhi P. Drug utilization pattern in the intensive care unit of a tertiary care hospital. J Clin Pharmacol 2006;46:945-51.","DOI":"10.1177\/0091270006289845"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"10. Garot D, Respaud R, Lanotte P, Simon N, Mercier E, Ehrmann S, et al. Population pharmacokinetics of ceftriaxone in critically ill septic patients: A reappraisal. Br J Clin Pharmacol 2011;72:758-67.","DOI":"10.1111\/j.1365-2125.2011.04005.x"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"11. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986;108 (5 Pt 2):835-40.","DOI":"10.1016\/S0022-3476(86)80754-5"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"12. Norrby SR, Bj\u00f6rneg\u00e5rd B, Ferber F, Jones KH. Pharmacokinetics of imipenem in healthy volunteers. J Antimicrob Chemother 1983;12 Suppl D: 109-24.","DOI":"10.1093\/jac\/12.suppl_D.109"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"13. Lefeuvre S, Marchand S, Lamarche I, Mimoz O, Couet W. Microdialysis study of imipenem distribution in the intraperitoneal fluid of rats with or without experimental peritonitis. Antimicrob Agents Chemother 2006;50:34-7.","DOI":"10.1128\/AAC.50.1.34-37.2006"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"14. Wathen CG, Carbarns NJ, Jones PA, Millar A, Croughan MJ, Calder MA, et al. Imipenem-cilastatin in the treatment of respiratory infections in patients with chronic airways obstruction. J Antimicrob Chemother 1988;21:107-12.","DOI":"10.1093\/jac\/21.1.107"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"15. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007;51:3304-10.","DOI":"10.1128\/AAC.01318-06"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"16. Sexton DJ, Wlodaver CG, Tobey LE, Yangco BG, Graziani AL, MacGregor RR. Twice daily intramuscular imipenem\/cilastatin in the treatment of skin and soft tissue infections. Chemotherapy 1991;37 Suppl 2:26-30.","DOI":"10.1159\/000238916"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"17. Craig WA. Pharmacokinetic\/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.","DOI":"10.1086\/516284"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"18. Jaruratanasirikul S, Raungsri N, Punyo J, Sriwiriyajan S. Pharmacokinetics of imipenem in healthy volunteers following administration by 2 h or 0.5 h infusion. J Antimicrob Chemother 2005;56:1163-5.","DOI":"10.1093\/jac\/dki375"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"19. van Zanten AR, Oudijk M, Nohlmans-Paulssen MK, van der Meer YG, Girbes AR, Polderman KH. Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: Pharmacokinetics\/pharmacodynamics, bacterial susceptibility and clinical efficacy. Br J Clin Pharmacol 2007;63:100-9.","DOI":"10.1111\/j.1365-2125.2006.02730.x"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"20. Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging NDM carbapenemases. Trends Microbiol 2011;19:588-95.","DOI":"10.1016\/j.tim.2011.09.005"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"21. Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994;38:931-6.","DOI":"10.1128\/AAC.38.5.931"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"22. Rodloff AC, Goldstein EJ, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother 2006;58:916-29.","DOI":"10.1093\/jac\/dkl354"}],"container-title":["Indian Journal of Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijccm.org\/doi\/pdf\/10.4103\/0972-5229.167036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T16:09:08Z","timestamp":1622131748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijccm.org\/doi\/10.4103\/0972-5229.167036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015]]}},"alternative-id":["10.4103\/0972-5229.167036"],"URL":"https:\/\/doi.org\/10.4103\/0972-5229.167036","relation":{},"ISSN":["0972-5229","1998-359X"],"issn-type":[{"value":"0972-5229","type":"print"},{"value":"1998-359X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}